Strategies involving anti-inflammatory drugs and inhibitors of pro-inflammatory cytokines, such as IL-6, TNF-α, and IL-1β, have also shown promise in remodeling the tumor microenvironment and alleviating immune exhaustion by reducing the chronic inflammation that sustains immunosuppression and tumor growth [50,51]. This evidence concerns the gene IL1B and neoplasm.